The funnel plot and Egger's test indicated the potential presence of publication bias.<h4>Conclusion</h4>Treatment with anti-EGFR monoclonal antibodies (mAbs) notably augments the risk of high grade infections in CRC patients, but does not significantly raise the risk of febrile neutropenia. This evidence concerns the gene EGFR and colorectal carcinoma.